osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,merck,janssen
['lcsm,(-blcsm)', 'lazertinib', 'sclc', 'nsclc', 'chrysalis-2', 'emd']
#asco22 for mutated advanced #lcsm #nsclc (egfrm)
shu et al. present #chrysalis-2, amivantamab + lazertinib post osi/chemo shows: orr: 33%, mdor: 9.6 mos in cohort a 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own